Top 3 Trends in Oncology That Will Soon Transform the Healthcare Industry
The advanced technology leveraged by the healthcare industry, especially in oncology platforms, will change the way the doctors and physicians think about treating cancer in the coming years.
FREMONT, CA: Advancement in Oncology technology will bring a huge impact in the next decade. The advanced development in drug technology is utilized especially for combination therapies, use of real-world evidence, and also for treatment and guidance of cancer care. At present, mobile trends are becoming quite popular. While a variety of apps focus on wellness and prevention, a huge number of them which is sponsored by pharma companies can access information and improve diagnosis and disease management. Here are some of the oncology technology trends to watch out for in the coming years.
Advanced Drug Development and Oncology Treatment Pipeline
Advanced cancer therapeutics comprises of the drug development activities involving immuno-oncology treatments, multiple drug treatment approaches, and also the identification of biomarkers, used in diagnostics testing and the development of focused therapies and biologics. Immuno-oncology treatments target the inhibitors that have proved to be effective in handling a number of different tumors. The pipeline of immuno-therapies is active. This includes almost 300 molecules with 60 mechanisms of the action for multiple indications. Apart from the individual therapeutics, the method of utilizing a multiple-drug treatment has expanded to the trend of immuno-oncology checkpoint inhibitors. Like most of the drugs that are developed are towards targeted therapies, which includes small molecules and biologics. Certain molecules are being targeted and studied for multiple targets or for utilizing the combination therapies. In oncology practices, the enhancing number of treatment protocols are based on the identification of distinct biomarkers that allow enhanced cancer care. At present, predictive biomarker and diagnostic testing can personalize the treatment, which leads to more-tolerable therapies, better treatment responses, and better outcomes.
The oncology practices rely on the data that range from clinical trials for informed clinical decision-making. Moreover, the available clinical trial data in oncology are limited because the treatments can be accepted on the basis of phase II trials; a lesser number of patients would be found in further trials. For this, the real evidence will help to fill these expanding knowledge gaps. As the real-world data typically acts as supportive evidence for the current trials or combined trial results. They are highly useful in expanding the information beyond the trial, like understanding disease progression, survival periods, and the treatment efficacy, for the indication of place or various patient subgroups. The real-world evidence guides personalized treatment, especially for discovering and promoting the new indications for the treatment combination. The largest challenges of using real-world evidence in practice are related to gathering the quality of data, data access, and governance of data.
Technology Advances to Impact Oncology
Advances in the biopharmaceuticals, comprising immuno-oncology, cell and gene therapies, and small-molecule mechanisms, will never have maintained without advances in technology. The non-invasive surgical interventions have also benefited from innovations, which includes the robotics and enhanced imaging techniques that can minimize the risk of problems. Along with this, another development that will benefit the cancer patients in the future is 3D printing and the potential of bio-printing to replace cancerous tissues or organs. The data science comprises of the real-world data, and artificial intelligence has the potential uses in the medical apps and telemedicine.
Telemedicine helps patients in remote areas who are immunocompromised or are immovable by recent surgery access to quality medical care. In addition, the growing adoption of medical apps can improve diagnosis by non-oncologists, drive better treatment adherence, and keep patients engaged in their cancer care.
By Leni Kaufman, VP & CIO, Newport News Shipbuilding
By George Evans, CIO, Singing River Health System
By John Kamin, EVP and CIO, Old National Bancorp
By Elliot Garbus, VP-IoT Solutions Group & GM-Automotive...
By Gregory Morrison, SVP & CIO, Cox Enterprises
By Alberto Ruocco, CIO, American Electric Power
By Sam Lamonica, CIO & VP Information Systems, Rosendin...
By Sergey Cherkasov, CIO, PhosAgro
By Pascal Becotte, MD-Global Supply Chain Practice for the...
By Stephen Caulfield, Executive Director, Global Field...
By Shamim Mohammad, SVP & CIO, CarMax
By Ronald Seymore, Managing Director, Enterprise Performance...
By Brad Bodell, SVP and CIO, CNO Financial Group, Inc.
By Jim Whitehurst, CEO, Red Hat
By Clark Golestani, EVP and CIO, Merck
By Scott Craig, Vice President of Product Marketing, Lexmark...
By Dave Kipe, SVP, Global Operations, Scholastic Inc.
By Meerah Rajavel, CIO, Forcepoint
By Amit Bahree, Executive, Global Technology and Innovation,...
By Greg Tacchetti, CIO, State Auto Insurance